United Therapeutics Corporation (UTHR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, United Therapeutics Corporation (UTHR) has a cash flow conversion efficiency ratio of 0.085x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($562.10 Million) by net assets ($6.59 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See UTHR equity to assets ratio to measure how much of total assets are equity-financed.
United Therapeutics Corporation - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how United Therapeutics Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of United Therapeutics Corporation to evaluate the quality of earnings relative to operating cash generation.
United Therapeutics Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of United Therapeutics Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CRRC Corp Ltd Class A
SHG:601766
|
-0.009x |
|
Telefonica SA ADR
NYSE:TEF
|
0.115x |
|
Church & Dwight Company Inc
NYSE:CHD
|
0.042x |
|
AXIA Energia SA
NYSE:AXIA-PC
|
0.023x |
|
Winbond Electronics Corp
TW:2344
|
0.100x |
|
SK Holdings Co Ltd
KO:034730
|
0.007x |
|
Coca-Cola Femsa SAB de CV ADR
NYSE:KOF
|
0.078x |
|
Bombardier Inc Series B
TO:BBD-B
|
-0.422x |
Annual Cash Flow Conversion Efficiency for United Therapeutics Corporation (1998–2024)
The table below shows the annual cash flow conversion efficiency of United Therapeutics Corporation from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of United Therapeutics Corporation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.44 Billion | $1.33 Billion | 0.206x | +26.03% |
| 2023-12-31 | $5.98 Billion | $978.00 Million | 0.163x | -2.32% |
| 2022-12-31 | $4.80 Billion | $802.50 Million | 0.167x | +10.72% |
| 2021-12-31 | $3.96 Billion | $598.20 Million | 0.151x | -32.11% |
| 2020-12-31 | $3.40 Billion | $755.70 Million | 0.223x | +399.54% |
| 2019-12-31 | $2.78 Billion | $-206.60 Million | -0.074x | -126.62% |
| 2018-12-31 | $2.79 Billion | $778.40 Million | 0.279x | +23.72% |
| 2017-12-31 | $2.10 Billion | $474.20 Million | 0.226x | -34.72% |
| 2016-12-31 | $1.86 Billion | $643.60 Million | 0.346x | +44.42% |
| 2015-12-31 | $1.60 Billion | $382.80 Million | 0.239x | -14.76% |
| 2014-12-31 | $1.27 Billion | $355.30 Million | 0.281x | -13.90% |
| 2013-12-31 | $1.30 Billion | $425.27 Million | 0.326x | +10.30% |
| 2012-12-31 | $1.09 Billion | $323.63 Million | 0.296x | +12.06% |
| 2011-12-31 | $948.49 Million | $250.19 Million | 0.264x | +10.22% |
| 2010-12-31 | $883.89 Million | $211.53 Million | 0.239x | +56.71% |
| 2009-12-31 | $653.01 Million | $99.72 Million | 0.153x | +257.60% |
| 2008-12-31 | $507.70 Million | $-49.20 Million | -0.097x | -158.56% |
| 2007-12-31 | $295.79 Million | $48.95 Million | 0.165x | -31.44% |
| 2006-12-31 | $204.61 Million | $49.39 Million | 0.241x | +53.83% |
| 2005-12-31 | $275.10 Million | $43.17 Million | 0.157x | +44.72% |
| 2004-12-31 | $191.64 Million | $20.78 Million | 0.108x | +312.45% |
| 2003-12-31 | $167.76 Million | $-8.56 Million | -0.051x | +60.64% |
| 2002-12-31 | $171.66 Million | $-22.26 Million | -0.130x | +34.53% |
| 2001-12-31 | $196.40 Million | $-38.90 Million | -0.198x | -49.42% |
| 2000-12-31 | $234.74 Million | $-31.11 Million | -0.133x | +70.02% |
| 1999-12-31 | $53.60 Million | $-23.70 Million | -0.442x | +23.08% |
| 1998-12-31 | $16.70 Million | $-9.60 Million | -0.575x | -- |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer;… Read more